General Proximity, a breakthrough biotech platform company, announced its emergence from stealth, unveiling its proprietary OmniTAC platform designed to pioneer the next generation of induced proximity medicines. The company has raised $16 million to accelerate the development of treatments targeting undruggable proteins associated with cancer, cardiometabolic disease, neurodegeneration, and longevity..

突破性的生物技术平台公司General Proxiency宣布其从隐形中崛起，推出其专有的OmniTAC平台，旨在开创下一代诱导近距离药物。。。

The oversubscribed seed round was led by Aydin Senkut, founder and managing partner at Felicis, a firm renowned for backing biotech trailblazers such as Recursion, Ginkgo Bioworks, and BioAge.

超额认购的种子轮由Felicis创始人兼管理合伙人艾丁·森库特（AydinSenkut）领导，Felicis是一家以支持Recursion、Ginkgo Bioworks和BioAge等生物技术先驱而闻名的公司。

Other notable investors include Y Combinator, age1, Modi Ventures, Wilson Sonsini, as well as a number of prestigious angel investors including Jeff Dean (Head of Google AI), Uri Lopatin (Khosla, YC, Pardes), Ben Mann (Co-Author GPT-3, Co-Founder Anthropic), Alec Nielsen (CEO Asimov), Trevor Martin (CEO Mammoth), Juan Benet (Founder Filecoin), Nish Bhat (Co-Founder Color Health), Jim Dahl (Rock Creek Capital), and De Thompson V (Legends Capital)..

其他著名投资者包括Y Combinator、age1、Modi Ventures、Wilson Sonsini，以及许多著名的天使投资者，包括Jeff Dean（谷歌AI负责人）、Uri Lopatin（科斯拉、YC、Pardes）、Ben Mann（合著者GPT-3、联合创始人Anthropic）、Alec Nielsen（首席执行官Asimov）、Trevor Martin（首席执行官Mammoth）、Juan Benet（创始人Filecoin）、Nish Bhat（联合创始人Color Health）、Jim Dahl（Rock Creek Capital）和De Thompson V（传奇资本）。。